Tag: Biotech and Pharma

Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry.

Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular ​obesity drug Zepbound to make the treatment more affordable for U.S. ‌patients, as demand for weight-loss therapies surge.

Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.

Shares of Novo Nordisk on Monday fell to a four-year low after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal.

Η Lavipharm A.E. ενημερώνει το επενδυτικό κοινό για τα βασικά ενοποιημένα οικονομικά μεγέθη του Εννεαμήνου 2025.

Johnson & Johnson (JNJ.N), said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, expanding the medtech conglomerate’s presence in solid tumors and prostate cancer treatments.

Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.

Shares of Metsera, fell nearly 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer, to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market.

Pfizer (PFE.N), on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster blood thinner helped it post third-quarter earnings above expectations.

Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda.

Eli Lilly (LLY.N), said on Wednesday it is partnering with Walmart (WMT.N), to expand access to Lilly’s weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.

Eli Lilly and Novo Nordisk stocks fell sharply early Friday after President Donald Trump suggested the price of blockbuster weight-loss medicines could come down substantially.

Abbott missed analysts’ estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices, sending its shares down 3% premarket.

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs.

 Pfizer (PFE.N) and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief.

 Pfizer (PFE.N), said on Monday it would acquire weight-loss drug developer Metsera (MTSR.O), in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment market.

Ο Όμιλος Lavipharm παρουσιάζει σημαντική αύξηση των ενοποιημένων πωλήσεων το α΄εξάμηνο σύμφωνα με τα οικονομικά αποτελέσματα που δημοσίευσε.

Eli Lilly’s international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration’s new fast-track review process for its experimental weight-loss pill orforglipron.